TFRC and Parkinson disease: For preclinical studies in a mouse PD or AD model, EPO was fused to the 8D3-derived TfRMAb, and the TfRMAb–EPO fusion protein retained high affinity binding for the mouse EPOR and mouse TfR1 [770].